10th International Workshop on Clinical Pharmacology of Tuberculosis Drugs – Presentations

 Sunday 15 October

 

Workshop Opening
Dr. R. Aarnoutse, Radboud University Medical Center, Nijmegen, Netherlands

  Session 1: Pharmacokinetics & Pharmacodynamics of New & Repurposed TB Drugs
Chairs: Rob Aarnoutse & Rovina Ruslami
 
Searching for a Universal Regimen for Tuberculosis Treatment with a Shorter Duration of Therapy (coming soon)
Dr. K. Mduli, TB Alliance, USA
  Abstract presentations
 "Exposure-Response Analysis of Lee 1810, a Lead Spectinamide Antibiotic in Mycobacterium tuberculosis Infected Mice"
Dr. S. Wagh, University of Tennessee Health Science Center, USA
 "Improved efficacy of a cofactor-independent InhA inhibitor revealed by the C3HeB/ FeJ mouse model"
Dr. G. Robertson, Colorado State University/ Mycobacteria Research Laboratories , USA
 "Pharmacokinetic modeling and simulation of pretomanid in pulmonary tuberculosis patients" (not available)
Dr. M. Lyons, Colorado State University, USA
 High dose rifampicin for the treatment of TB meningitis: a dose finding study
Dr. R. Aarnoutse , Radboud University Medical Center, Nijmegen , Netherlands
  Session 2: Pharmacokinetics & pharmacodynamics of approved TB drugs
Chairs: Gerry Davies & Paolo Denti
 
"A Cardiac Risk Algorithm to Predict the Probability of Drug-Induced Torsades de Pointes with Novel Anti-TB Agents"
Dr. A. Berg, Critical Path Institute; Tucson, AZ, USA
  Abstract presentations
 "Optimizing the Dose of Levofloxacin: Pharmacokinetic Results from the Opti-Q Study" (Not available)
Dr. C. Peloquin, University of Florida, USA
 "Ototoxicity is associated with exposure to kanamycin and capreomycin in the treatment of multidrug-resistant tuberculosis"
Dr. M. Alshaer, University of Florida, USA
 Pyrazinamide sterilizes necrotic lesions in tuberculosis infected lungs (not available)
Dr. V. Dartois, Rutgers University, USA
 Moxifloxacin as the fluoroquinolone of choice to treat TB? (not available)
Dr. J. Sarathy, Rutgers University, USA
  Session 3: Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Modelling
Chairs: Khisi Mdluli & Dakshina Chilukuri
 
Benefits of data collaboration – personalized tailoring regimens (not available)
Dr. R. Savic, University of California, USA
  Abstract presentations
 "Pharmacokinetics of rifampicin in African children - Evaluation of the new WHO dosing guidelines"
Dr. P. Denti, University of Cape Town, South Africa
 "Prediction of increase in time-to-positivity after higher doses of rifampicin based on pharmacokinetic-pharmacodynamic modelling"
Dr. R. Svensson, Uppsala University, Sweden
 "Relating rifampicin exposure to treatment response in patients with pulmonary tuberculosis – potential for treatment shortening with higher doses" (Not available)
Dr. E. Svensson, Radboud University Medical Center, Nijmegen, Netherlands
 "Population Pharmacokinetic Modeling of Clofazimine in Adult Tuberculosis Patients: Implications for Dosing" (not available)
Dr. N. Zhang, University of California, USA
  Session 4: Drug development and optimization: approaches and tools
Chairs: Eric Nuermberger & Charles Peloquin
  Abstract presentations
 "Quantitative Analysis of MGIT Time to Positivity Using a Two-Part Longitudinal Model in Patients with Pulmonary Tuberculosis: A Meta-Analysis of 11 Clinical Studies Including 30 Unique Regimens"
Dr. N. Kassir, Certara, Canada
 "Influence of Bacterial Growth Rate on Dose Optimization of Linezolid for Treatment of Tuberculosis"
Dr. K. Bigelow, Johns Hopkins University, USA
 "A pharmacokinetic/pharmacodynamic drug-drug interaction study of rifampicin and metformin in type II diabetic tuberculosis patients" (Not available)
L. te Brake, Radboud University Medical Center, Nijmegen, Netherlands
 Personalized tuberculosis treatment through Bayesian dosing of rifampicin (Not available)
Dr. S. van Beek, Radboud University Medical Center, Nijmegen, Netherlands